Insulet Corporation — Q3 2012 Form 10-Q
Business context and period. This unaudited quarterly report covers the three and nine months ended September 30, 2012. Insulet sells its OmniPod insulin management system and other diabetes supplies, including products added through its 2011 Neighborhood Diabetes acquisition. Amounts below are in U.S. dollars; financial statement figures are converted from thousands to millions where appropriate.
Financial performance and liquidity
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Revenue | $54.8m | $44.6m | $153.5m | $105.1m |
| Gross profit | $24.4m | $18.6m | $67.0m | $46.6m |
| Gross margin | 44.5% | 41.6% | 43.6% | 44.4% |
| Operating loss | $(8.5)m | $(9.8)m | $(29.9)m | $(32.0)m |
| Net loss | $(12.4)m | $(13.6)m | $(41.7)m | $(42.8)m |
| Net loss per share | $(0.26) | $(0.29) | $(0.87) | $(0.92) |
- Revenue grew 23% in Q3 and 46% year to date. Management attributed Q3 growth to continued OmniPod adoption in the U.S. and internationally and increased sales of other diabetes supplies. The year-to-date increase also reflected the Neighborhood Diabetes acquisition.
- Gross profit rose, but cost of revenue also increased with sales volume. Nine-month gross margin declined 0.8 percentage points year over year. Operating expenses increased 16% in Q3 and 23% year to date; higher revenue nevertheless narrowed operating and net losses.
- For the first nine months, operating cash use was $23.5m, versus $17.8m in 2011; investing cash use was $8.9m, versus $46.7m, primarily reflecting manufacturing equipment purchases in 2012 versus the prior-year acquisition. Financing provided $1.9m, compared with $55.0m in 2011.
- Cash and cash equivalents were $63.4m at September 30, down from $94.0m at December 31, 2011. Current assets were $113.4m and current liabilities $49.3m. The filing reports total debt of $115.7m net of $43.1m unamortized discount; principal outstanding was $158.8m. Of that principal, $15.0m of 5.375% notes matures in June 2013, and $143.8m of 3.75% notes matures in June 2016.
Changes, outlook and material risks
- Management expected 2012 revenue to continue increasing, but provided no quantified revenue or earnings guidance. It expected near-term losses to continue while investing in growth and the next-generation OmniPod.
- Near-term priorities included U.S. FDA approval of the next-generation OmniPod, manufacturing capacity and launch activity in certain European countries. Management expected R&D spending to remain around current levels, G&A spending to decrease, and sales and marketing expenses to increase during the remainder of 2012.
- Management said cash, cash equivalents and expected product-sale cash generation should cover projected operating and debt-service requirements for at least 12 months. This is a forward-looking assessment, not a guarantee; the 2013 note maturity is a significant near-term funding consideration.
- Manufacturing depends substantially on one facility in China, while substantially all inventory is held at one Massachusetts location. The filing also cites reimbursement, supplier, manufacturing-cost, regulatory approval, competition, financing and growth-management risks.
- Patent litigation is pending: BD’s 2010 case alleges infringement of three patents; Medtronic filed a separate suit in October 2012 alleging infringement of two patents described as material to the business. Insulet denies infringement and says it has meritorious defenses, while acknowledging litigation uncertainty and possible injunctions, costs or business disruption.
- A Massachusetts sales-and-use-tax audit concerns Neighborhood Diabetes periods before its acquisition. Insulet recorded an estimated liability and a corresponding indemnification asset; former owners agreed to indemnify certain pre-acquisition tax liabilities. The filing does not state a clear amount for the estimate.
- No goodwill impairment was recorded in the first nine months of 2012. The filing reports no material impact from the 2012 adoption of the cited accounting standards and no material change in internal control over financial reporting.
Most important facts for investors to verify
- How Insulet plans to address the $15.0m note maturity in June 2013, and whether cash generation or other financing will be sufficient.
- Whether revenue growth translates into sustainable margin improvement and lower operating cash use; receivables and inventory rose during the first nine months.
- The timing and outcome of U.S. regulatory approval and launch of the next-generation OmniPod, and the associated investment and production ramp.
- Developments in the BD and Medtronic patent cases, including potential injunctions, damages, licensing costs or operational effects.
- Progress in reimbursement access, supplier reliability, manufacturing concentration and the Massachusetts tax audit/indemnification.